Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
Tóm tắt
Diabetic macular oedema (DMO) remains a significant cause of sight loss in the UK. Despite macular laser and anti-VEGF agents, a large proportion of patients remain with persistent DMO. We present our results of using 0.19 mg fluocinolone acetonide (FAc) intravitreal implant in this cohort with up to 3 years of follow-up. This is a single-centre retrospective review of patients treated with FAc implant for refractory DMO. The primary efficacy end point was visual acuity and secondary efficacy end point was central retinal thickness (CRT) on OCT. A primary safety end point was a rise in IOP requiring treatment. Twenty-one eyes were identified with an average follow-up of 27 months (6–36 months). Visual acuity change from baseline was − 0.1 ETDRS letters at year 1 (n = 13), 8.1 letters at year 2 (n = 13) and 10.7 letters at year 3 (n = 10). CRT improved by − 132.1 µm at year 1 (n = 15), − 172.8 µm at year 2 (n = 13) and − 157.8 µm at year 3 (n = 10). Five eyes (24%) required further anti-VEGF during follow-up and two (9.5%) required further focal laser. IOP rise requiring treatment was noted in eight eyes (38%). Seven were steroid induced. One was caused by rubeotic glaucoma. Six (75%) were managed medically and the remaining two also required surgery. This data add to the limited real-world data on FAc in DMO with 3 years of follow-up. Vision and macular architectures both improved at varying rates over 3 years in patients with refractory DMO. IOP rise is a risk but, in the majority, it can be managed medically.
Tài liệu tham khảo
Klein R, Klein BE, Moss SE, Cruickshanks KJJO. The Wisconsin epidemiologic study of diabetic retinopathy XV: the long-term incidence of macular edema. Ophthalmology. 1995;102(1):7–16.
Das A, McGuire PG, Rangasamy SJO. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–94.
Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28(Suppl):452–61.
Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges RJJodr. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016;2016:2156273.
Powers M, Greven M, Kleinman R, Nguyen QD. Recent advances in the management and understanding of diabetic retinopathy. F1000Res 2017;6:2063.
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103(12):1796–806.
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.
Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376–85.
Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257–69.
Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi RJ. Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. Investig Ophthalmol Vis Sci. 2009;50(10):4847–57.
Inc AS. Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection. 2014.
Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32.
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after inadequate response to prior therapy. National Institute for Health and Care Excellence; 2013.
Authority DVL. Driving eyesight rules. https://www.gov.uk/driving-eyesight-rules.
Fusi-Rubiano W, Mukherjee C, Lane M, Tsaloumas MD, Glover N, Kidess A, et al. Treating diabetic macular oedema (DMO): real world UK clinical outcomes for the 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at 2 years. BMC Ophthalmol. 2018;18(1):62.
Augustin AJ, Bopp S, Fechner M, Holz F, Sandner D, Winkgen A-M, et al. Three-year results from the Retro-IDEAL study: real-world data from diabetic macular edema (DME) patients treated with ILUVIEN® (0.19 mg fluocinolone acetonide implant). Eur J Ophthalmol. 2019. https://doi.org/10.1177/1120672119834474.